ArticleJAMA network open2026

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma.

Eusebio Luna Velasquez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.